NCT07457151Recruiting
Danicopan PMS in Korea
Danicopan Regulatory Post-Marketing Study in Korea
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Danicopan under conditions of routine daily medical practice in Korea.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 27 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- 10 Apr 2026
- Primary completion date
- 27 Jun 2028
- Lead sponsor
- AstraZeneca
- NCT number
- NCT07457151
What you commit to
- Study type: Observational
- Planned participants: 27
- From 10 Apr 2026 to the primary completion date, 27 Jun 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in any concurrent interventional trials during the period of study drug treatment
Other
- Other off-label indications according to the approved label in Korea
Who the study is looking for
- Patients eligible for and treated with Danicpan as add-on therapy to a C5 inhibitor (Eculizumab or Ravulizumab) in patient with PNH in Korea
- Provision of a signed and dated written informed consent by the patient or their legally acceptable representative
Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Site Coordinator of this site? Confirm its status | Busan | South Korea | Recruiting |
| Research Site Coordinator of this site? Confirm its status | Hwasun-gun | South Korea | Recruiting |
| Research Site Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.